US 11,767,344 B2
Pharmaceutically acceptable salts of polypeptides and methods of inhibiting the interaction between psd-95 and n-methyl-d-aspartic acid receptor (nmdar)
Huamin Han, Beijing (CN); Yujia Tian, Beijing (CN); and Hongjun Jia, Beiing (CN)
Assigned to BIOCELLS (BEIJING) BIOTECH CO., LTD., Beijing (CN)
Appl. No. 16/628,083
Filed by BIOCELLS (BEIJING) BIOTECH CO., LTD., Beijing (CN)
PCT Filed Jul. 5, 2017, PCT No. PCT/CN2017/091792
§ 371(c)(1), (2) Date Mar. 11, 2020,
PCT Pub. No. WO2019/006690, PCT Pub. Date Jan. 10, 2019.
Prior Publication US 2020/0385425 A1, Dec. 10, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/00 (2006.01); A61K 38/39 (2006.01); C07K 7/00 (2006.01); C07K 14/00 (2006.01); C07K 4/00 (2006.01); C07K 14/475 (2006.01); C07K 14/48 (2006.01); C07K 7/08 (2006.01); A61P 9/10 (2006.01); A61K 9/19 (2006.01); A61K 47/22 (2006.01); A61K 47/26 (2006.01)
CPC C07K 7/08 (2013.01) [A61K 9/19 (2013.01); A61K 38/00 (2013.01); A61K 47/22 (2013.01); A61K 47/26 (2013.01); A61P 9/10 (2018.01); C07K 2319/10 (2013.01)] 18 Claims
 
1. A pharmaceutically acceptable salt of a peptide, wherein the peptide comprises the amino acid sequence YEKLLDTEI (SEQ ID NO:1) or a functional variant thereof, wherein the functional variant is a variant only having one or more conservative substitutions in YEKLLDTEI (SEQ ID NO:1), wherein the conservative substitution is selected from the group consisting of a substitution between D and E, a substitution among L, V and I, and a substitution between T and S, wherein the peptide or the functional variant thereof is capable of binding to the PSD-95/Discs-large/ZO-1 1/2 domain (PDZ1/2) domain of postsynaptic density 95 protein (PSD-95) and inhibiting the interaction between PSD-95 and N-methyl-D-aspartic acid receptor (NMDAR), and wherein the salt is an acetate.